Article
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
Future oncology (London, England) - 1 Mar 2018
DeLeon Thomas T, Ahn Daniel H, Bogenberger James M, Anastasiadis Panos Z, Arora Mansi, Ramanathan Ramesh K, Aqel Bashar A, Vasmatzis George, Truty Mark J, Oklu Rahmi, Bekaii-Saab Tanios S, Borad Mitesh J
Abstract excerpt
Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.